收费全文 | 2452篇 |
免费 | 143篇 |
国内免费 | 17篇 |
耳鼻咽喉 | 13篇 |
儿科学 | 109篇 |
妇产科学 | 67篇 |
基础医学 | 441篇 |
口腔科学 | 34篇 |
临床医学 | 308篇 |
内科学 | 480篇 |
皮肤病学 | 50篇 |
神经病学 | 235篇 |
特种医学 | 46篇 |
外科学 | 185篇 |
综合类 | 14篇 |
预防医学 | 221篇 |
眼科学 | 28篇 |
药学 | 217篇 |
中国医学 | 3篇 |
肿瘤学 | 161篇 |
2023年 | 17篇 |
2022年 | 19篇 |
2021年 | 47篇 |
2020年 | 32篇 |
2019年 | 47篇 |
2018年 | 67篇 |
2017年 | 46篇 |
2016年 | 55篇 |
2015年 | 64篇 |
2014年 | 90篇 |
2013年 | 119篇 |
2012年 | 185篇 |
2011年 | 204篇 |
2010年 | 111篇 |
2009年 | 99篇 |
2008年 | 167篇 |
2007年 | 159篇 |
2006年 | 153篇 |
2005年 | 140篇 |
2004年 | 120篇 |
2003年 | 124篇 |
2002年 | 111篇 |
2001年 | 31篇 |
2000年 | 29篇 |
1999年 | 38篇 |
1998年 | 33篇 |
1997年 | 20篇 |
1996年 | 21篇 |
1995年 | 13篇 |
1994年 | 12篇 |
1993年 | 8篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1990年 | 13篇 |
1989年 | 17篇 |
1988年 | 14篇 |
1987年 | 13篇 |
1986年 | 14篇 |
1985年 | 14篇 |
1984年 | 10篇 |
1983年 | 6篇 |
1980年 | 8篇 |
1979年 | 10篇 |
1977年 | 10篇 |
1976年 | 8篇 |
1974年 | 5篇 |
1973年 | 8篇 |
1972年 | 6篇 |
1971年 | 5篇 |
1967年 | 6篇 |
Purpose
The study aim was to evaluate patient acceptance and content with remote follow-up (FU) of their implantable cardioverter defibrillator (ICD) and to estimate patients?? wish for changes in remote follow-up routines.Methods
Four hundred seventy-four ICD patients at the device follow-up clinic at Rigshospitalet using CareLink? (Medtronic) remote follow-up, who had made ??2 transmissions, received a questionnaire.Results
Three hundred eighty-five patients (81.2%) answered. Mean time with ICD was 56?±?45?months and mean age was 62?±?13?years; 80% was male. Diagnosis related to ICD implant was: ischemic heart disease in 56% and dilated cardiomyopathy in 21%. Twenty-six percent had primary prophylactic indication. Mean time on remote FU was 16.4?±?6.9?months. Mean time spent on in-clinic FU (two-way transport and FU) was 4?h and 36?min?±?7?h and 50?min, excluding 12 patients from Greenland and Faroe Islands. Ninety-five percent of the patients was very content or content with remote FU compared to in-clinic FU; 3% was less content and 2% was not content. For scheduled transmissions, 21% of the patients wished for a faster reply (sms or e-mail) compared to current practice with a letter. Eighty-four percent preferred more detailed information concerning ICD leads, battery status, and ICD therapies. A total of 96 patients (25%) had performed extra unscheduled remote transmissions: 20 due to shock, 20 due to alarm, 35 due to palpitations, and 18 for other or combined reasons.Conclusion
Ninety-five percent of the patients were content with the remote FU. Only 25% had unscheduled transmissions and most unscheduled transmissions were for appropriate reasons. Eighty-four percent of the patients wished for a more detailed response and 21% wished for a faster reply after routine transmissions. 相似文献Background
HIV-associated general immune activation is a strong predictor for HIV disease progression, suggesting that chronic immune activation may drive HIV pathogenesis. Consequently, immunomodulating agents may decelerate HIV disease progression. 相似文献Introduction and hypothesis
To prospectively evaluate the use of a particular polypropylene Y mesh for robotic sacrocolpopexy.Methods
This was a prospective study of 120 patients who underwent robotic sacrocolpopexy. We compared preoperative and 12-month postoperative objective and subjective assessments via the Pelvic Organ Prolapse Quantification (POP-Q), the Pelvic Floor Distress Inventory, Short Form 20 (PFDI-20); the Pelvic Floor Impact Questionnaire, Short Form 7 (PFIQ-7); and the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire 12 (PISQ-12). Objective “anatomical success” was defined as POP-Q stage 0 or 1 at all postoperative intervals. We further defined “clinical cure” by simultaneously considering POP-Q points and subjective measures. To be considered a “clinical cure,” a given patient had to have all POP-Q points ≤0, apical POP-Q point C ≤5, no reported pelvic organ prolapse symptoms on the PFDI-20, and no reoperation for prolapse at all postoperative intervals.Results
Of the 120 patients, 118 patients completed the 1-year follow-up. The objective “anatomical success” rate was 89 % and the “clinical cure” rate was 94 %. The PFDI-20 mean score improved from 100.4 at baseline to 21.0 at 12 months (p?<?0.0001); PFIQ-7 scores improved from 61.6 to 8.0 (p?<?0.0001); and PISQ-12 scores improved from 35.7 to 38.6 (p?<?0.0009). No mesh erosions or mesh-related complications occurred.Conclusion
The use of this ultra-lightweight Y mesh for sacrocolpopexy, eliminated the mesh-related complications in the first postoperative year, and provided significant improvement in subjective and objective outcomes. 相似文献Evidence-based policy measures need non-interest-guided information about the health status of a population and the diseases that affect the population the most. In such cases, a national burden of disease study can provide reliable insights at the regional level.
AimThis article presents the potential of the BURDEN 2020 project and its expected outcome for Germany at the national and regional level.
MethodsThe BURDEN 2020 project uses several indicators including years of life lost (YLL) to cover the impact of mortality and years lived with disability (YLD) to cover morbidity. The sum of both is the measure of population health called disability adjusted life years (DALY).
ResultsThe study ranks individual diseases and risk factors based on their impact on population health. The burden of disease approach is assumed to be sensitive to subnational differences and may generate immediate benefits for regional planning. The BURDEN 2020 study will pilot a national burden of disease study for Germany that will later be transformed into a continuous data processing and visualization tool. This is done by using, modifying and supplementing the methodology employed by the Global Burden of Disease (GBD) study to better fit the needs of health policy in Germany. This study is aimed at calculating the disease burden for up to 17 preselected diseases. Furthermore, the estimates of burden of disease are attributed to a selected set of risk factors.
ConclusionThe Burden 2020 study will provide the results of a new, health-related data processing system to the public. This includes a noninterest-guided presentation of the burden of disease (DALY) in Germany at the national and regional level.
相似文献